Trials / Completed
CompletedNCT00431873
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGCD0103 | MGCD0103 Administered orally three times per week. |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-02-06
- Last updated
- 2015-07-01
Locations
13 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00431873. Inclusion in this directory is not an endorsement.